{
    "code": "52028283",
    "url": "https:\/\/info.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=52028283",
    "time": "2024-04-18 20:00:24",
    "許可證字號": "衛部藥輸字第028283號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "製造許可登錄編號": "",
    "有效日期": "116\/03\/22",
    "發證\/登錄日期": "111\/03\/22",
    "許可證\/登錄種類": "製　劑",
    "舊證字號": "",
    "醫療器材級數": "",
    "第一等級醫療器材原許可證字號": "",
    "第一等級醫療器材新登錄字號": "",
    "通關簽審文件編號": "DHA05202828301",
    "中文品名": "萊利邁膠囊10毫克",
    "英文品名": "LELIMIDE 10 (Lenalidomide Capsules 10mg)",
    "適應症": "1. 多發性骨髓瘤(Multiple Myeloma，MM)： \r\n(1) 與dexamethasone、與bortezomib及dexamethasone、或與melphalan及prednisone合併使用治療不適合接受移植之新診斷多發性骨髓瘤(multiple myeloma，MM)成年病人。\r\n(2) 單一療法適用於做為已接受自體造血幹細胞移植之新診斷多發性骨髓瘤成年病人的維持治療用藥。\r\n(3) 與dexamethasone合併使用可治療先前已接受至少一種治療失敗之多發性骨髓瘤病人。 \r\n2. 骨髓增生不良症候群(Myelodysplastic syndromes，MDS)：在其他治療方式不佳的情況下，Lenalidomide可單獨用於治療IPSS分級為低或中度(Intermediate-1)風險且單獨伴隨染色體5q缺失之骨髓增生不良症候群(Myelodysplastic syndromes，MDS)所導致的輸血依賴型貧血之成人病人。 \r\n3. 濾泡性淋巴瘤(Follicular Lymphoma，FL)：與rituximab合併使用，治療先前已接受過治療之濾泡性淋巴瘤(follicular lymphoma，FL)成年病人。",
    "劑型": "130膠囊劑",
    "包裝": "2-1000錠ALU-ALU鋁箔盒裝",
    "儲存溫度": "",
    "有效期間": "",
    "指示藥品審查基準": "",
    "標籤、仿單及包裝加註": "",
    "藥品類別": "06須由醫師處方使用",
    "管制藥品分類級別": "",
    "藥品分類": "監視期滿學名藥;",
    "監視期限": "",
    "主成分略述": "LENALIDOMIDE",
    "限制項目": "02輸　入 1D須執行風險管理計畫 24監視期滿學名藥",
    "申請商名稱": "凱沛爾藥品有限公司",
    "申請商地址": "臺北市信義區光復南路495號6樓",
    "主製造廠": [
        {
            "製造廠名稱": "HETERO LABS LIMITED, UNIT V",
            "製造廠廠址": "SY. NO 439, 440, 441 &amp; 458, TSIIC FORMULATION SEZ, POLEPALLY VILLAGE, JADCHERLA MANDAL, MAHABOOBNAGAR DISTRICT, TELANGANA, INDIA",
            "製造廠公司地址": "",
            "製造廠國別": "INDIA",
            "製程": ""
        }
    ],
    "CCC號列": "",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "1008200300",
            "成分名稱": "LENALIDOMIDE",
            "含量描述": "Lenalidomide IH (Form H1)",
            "含量": "10.0000000000",
            "單位": "MG"
        }
    ],
    "藥物辨識詳細資料": {
        "外觀尺寸": "",
        "特殊劑型": "",
        "顏色": "",
        "特殊氣味": "",
        "刻痕": "",
        "形狀": "",
        "標記一": "",
        "標記二": ""
    },
    "藥物辨識外觀圖片": [
        {
            "title": "藥物外觀-111-05-09.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52028283&Seq=001&Type=10"
        }
    ],
    "仿單外盒": [
        {
            "title": "2076033 Lelimide Leaflet-112-10-31(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52028283&Seq=002&Type=9"
        },
        {
            "title": "仿單擬稿-111-05-09.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52028283&Seq=001&Type=9"
        },
        {
            "title": "鋁箔擬稿-111-05-09.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52028283&Seq=002&Type=8"
        },
        {
            "title": "外盒擬稿-111-05-09.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52028283&Seq=001&Type=8"
        }
    ]
}